Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

NCT04402580 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Stopped due to unexpectedly high rate of relapse in the active comparator arm.

Conditions

Nephrotic Syndrome Steroid-Dependent

Interventions

DRUG: Rituximab Biosimilar
DRUG: Mycophenolate Mofetil

Sponsor

Istituto Giannina Gaslini

Collaborators

[object Object]